39
Participants
Start Date
November 30, 2013
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
selumetinib (oral)
Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
Research Site, Overland Park
Lead Sponsor
AstraZeneca
INDUSTRY